Fidelity High Dividend ETF's Index reconstituted effective Monday, resulting in substantial sector allocation changes and an improved dividend yield, now expected to be 3.22%. Despite the changes, FDVV's fundamentals remain solid. The portfolio's expected earnings growth rate is in the high-single-digits and FDVV's forward P/E ratio dropped from 18.00x to 16.68x. There was a slight deterioration in quality, but that's mainly due to increased exposure to Financials sector stocks, where metrics like ROA tend to be lower.

The offering resulted in aggregate gross proceeds of USD920 million, of which EQT received c. USD393 million NEW YORK , Feb. 24, 2025 /PRNewswire/ -- An affiliate of the fund known as EQT VIII ("EQT") is pleased to announce the completion of an underwritten public offering (the "Offering") of 23 million shares of common stock of Waystar Holding Corp. (NASDAQ: WAY) (the "Company") ("Shares") for aggregate gross proceeds of USD920 million.

Brad Smith takes a closer look at the top issues you need to know to empower your personal finances. Penn Mutual Asset Management portfolio manager George Cipolloni outlines which components investors should watch to make the best trade decisions amid economic and political uncertainty.

LONDON--(BUSINESS WIRE)--Pentair plc (NYSE: PNR) announced today that it will pay a regular quarterly cash dividend of $0.25 per share on May 2, 2025 to shareholders of record at the close of business on April 18, 2025. This is the 49th consecutive year that Pentair has increased its dividend. ABOUT PENTAIR PLC At Pentair, we help the world sustainably move, improve, and enjoy water, life's most essential resource. From our residential and commercial water solutions, to industrial water managem.

PubMatic's Next Act: A Likely Value Play In Ad Tech

Q2 Holdings: Buy This Little-Known Software Company As It Ramps Up RPOs And EBITDA

TORONTO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2024 fourth-quarter and full-year earnings conference call on Thursday, February 27, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2024 lead plaintiff deadline.

Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity

DENVER , Feb. 24, 2025 /PRNewswire/ -- Apartment Investment and Management Company ("Aimco") (NYSE: AIV) announced today fourth quarter and full year 2024 results and established 2025 guidance. Financial Results Aimco's net loss attributable to common stockholders per share, on a fully dilutive basis, was $(0.08) for the quarter, and $(0.75) for the year ended December 31, 2024.

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Neumora Therapeutics, Inc.(NASDAQ:NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Neumora common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PALM BEACH GARDENS, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Dycom Industries, Inc. (NYSE: DY) announced today that the Company will participate in the following upcoming institutional investor conferences:

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=131882&wire=1 or contact Joseph E. Levi, Esq.

Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical analysis for narsoplimab's BLA resubmission, which proved successful, leading to a potential approval by late 2025. Financial risks include limited cash runway and potential market constraints due to upcoming generic competition and insurance issues.

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading. The company's margin of

Hovnanian Enterprises, Inc. (NYSE:HOV ) Q1 2025 Earnings Conference Call February 24, 2025 11:00 AM ET Company Participants Jeff O'Keefe - Vice President, Investor Relations Ara Hovnanian - Chairman, President and CEO Brad O'Connor – Chief Financial Officer David Mitrisin - Vice President, Corporate Controller Paul Eberly - Vice President, Finance and Treasurer Conference Call Participants Alan Ratner - Zelman & Associates Alex Barron - Housing Research Center Jay McCanless - Wedbush Operator Good morning and thank you for joining us today for Hovnanian Enterprises Fiscal 2025 First Quarter Earnings Conference Call. An archive of the webcast will be available …

— 50% improvement in Net Loss and 43% improvement in Adjusted EBITDA year-over-year, driven by exceeding our gross margin expansion and fixed cost reduction goals in our core business — — Continued ramp of our Overstock brand, SKU/vendor refinement, pricing and discounting discipline within Bed Bath & Beyond banner, BuyBuyBaby acquisition and completion of material stake in Kirkland's Home provides a clear path to our goal of growth and profitability — MURRAY, Utah, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beyond, Inc. (NYSE:BYON), owner of Bed Bath & Beyond and Overstock, today reported financial results for the fourth quarter and full …

Full Year Operating Income Increases to $103.5 million Full Year Adjusted EBITDAre Grows to $192.2 million; AFFO increases 5.6% to $0.96 per share Completed Over $200 Million of Accretive Transaction Activity in 2024 AUSTIN, Texas , Feb. 24, 2025 /PRNewswire/ -- Summit Hotel Properties, Inc. (NYSE: INN) (the "Company"), today announced results for the three and twelve months ended December 31, 2024. "We are pleased with our fourth quarter and full-year 2024 financial results, driven by pro forma RevPAR growth that exceeded industry average growth for the third consecutive year, effective expense management, and the continued success of our accretive …

NEW YORK--(BUSINESS WIRE)--The New Germany Fund, Inc. (NYSE: GF) (the “Fund”) announced today that Hansjoerg Pack will replace Leon Cappel as the Fund's portfolio manager effective March 1, 2025. The Fund noted that Mr. Cappel had decided to resign as the Fund's portfolio manager for personal reasons, and that the Fund's Deputy Portfolio Manager would continue to be Juan Barriobero de la Pisa. Mr. Pack joined DWS in 1997 and has extensive portfolio management experience, including management of.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 5,550 shares of the Company's common stock at an exercise price per share of $11.07, which was the closing price on February 21, 2025, and.